cbdc newfoundland, Knowledge graph

On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Six residential plots in Wuhan received 5.457 billion yuan: OCT received 2.42 billion yuan from Yangchun Lake. According to the monitoring of the China Central Finger Research Institute, on December 13th, Wuhan successfully sold six residential plots, including Hanyang District, Donghu High-tech Zone, Hongshan District, huangpi district District and Qingshan District. The total land area of 6 plots is 214,964 ㎡, the total planned construction area is 726,285.4 ㎡, and the total starting price is 5.457 billion yuan. In the end, all six plots were sold at the reserve price, with a total income of 5.457 billion yuan, including Yangchun Lake in Hongshan District, OCT, and Hanyang District, Wuhan Huijing Real Estate, a private enterprise.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.

Wuzhou Spring today bought 101 million yuan and sold 140 million yuan on Shanghai Stock Connect. Wuzhou Spring today traded at a daily limit, with a turnover of 4.335 billion yuan and a turnover rate of 35.76%. After-hours data showed that Ningbo Sangtian Road mat bought 77.1945 million yuan, and Shanghai Stock Connect special seats bought 101 million yuan and sold 140 million yuan.Qinchuan Machine Tool: The company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers. Qinchuan Machine Tool said on the interactive platform that the company's machine tool business section can provide a variety of processing equipment for humanoid robot manufacturers, such as gear grinder, planetary roller screw pair key processing equipment thread grinder, etc. The spare parts business section of the company has the foundation of R&D and manufacturing of planetary roller screw by-products. Now, it has gradually started small batch production and verified its application. In the future, according to the market demand, it will gradually improve the detection and processing means and build its capacity.Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.

On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Deutsche Bank: There is little hope that the British economy will rebound at the end of the year. Sanjay Raja, an economist at Deutsche Bank, wrote in a research report that the British economy will face more twists and turns in the future. Data released on Friday showed that Britain's GDP contracted again in October from the previous month, which surprised the market. Raja said that business surveys predict that economic activity will further weaken in the last few months of this year. In his research report, he reminded investors that the uncertainty in taxation and expenditure, coupled with the reduction in retail and service consumption caused by bad weather, added more resistance to Britain's fragile economic recovery.